Analysts reset AbbVie stock price target after earnings
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
AbbVie expects Humira access to decrease throughout 2025
Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...
MarketWatch6d
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...
AbbVie price target raised to $215 from $205 at Citi
Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in ...